Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03263611
Recruitment Status : Recruiting
First Posted : August 28, 2017
Last Update Posted : August 17, 2018
Sponsor:
Information provided by (Responsible Party):
AnGes, Inc.

Brief Summary:
This clinical trial evaluate the safety, tolerability and exploratory efficacy of targeted single injection of AMG0103 in subject with chronic discogenic lumbar back pain

Condition or disease Intervention/treatment Phase
Degenerative Disc Disease Drug: Placebo Drug: AMG0103 Phase 1

Detailed Description:

This is a Phase 1b, multicenter, double-blind, single ascending dose study designed to evaluate the safety of AMG0103 in adult male and female subjects with chronic discogenic lumbar back pain.

This protocol anticipates that 8 subjects with symptomatic single level discogenic pain will be enrolled in each of up to 3 dose-escalation cohorts. Subjects in each cohort will receive AMG0103 or Placebo as a targeted, single, intradiscal injection.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1b, Multicenter, Double-blind, Randomized, Placebo-controlled, Single Ascending-Dose, Clinical Study Evaluating the Safety, Tolerability and Exploratory Efficacy of a Targeted Single Injection of an Intradiscal Nuclear Factor-κB Decoy Oligodeoxynucleotide (AMG0103) in Subjects With Chronic Discogenic Lumbar Back Pain
Actual Study Start Date : February 26, 2018
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Placebo Comparator: placebo
subject will receive single intradiscal injection of placebo
Drug: Placebo
single intradiscal injection

Experimental: AMG0103 low dose
subject will receive single intradiscal injection of AMG0103 low dose
Drug: AMG0103
single intradiscal injection

Experimental: AMG0103 middle dose
subject will receive single intradiscal injection of AMG0103 middle dose
Drug: AMG0103
single intradiscal injection

Experimental: AMG0103 high dose
subject will receive single intradiscal injection of AMG0103 high dose
Drug: AMG0103
single intradiscal injection




Primary Outcome Measures :
  1. Safety: treatment-emergent adverse events (AEs) [ Time Frame: 6 months ]
  2. Safety: data from 12-lead electrocardiograms [ Time Frame: 6 months ]
  3. Safety: data from clinical laboratory evaluations (hematology, serum chemistry, coagulation, inflammation and immunology) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Visual Analogue Scale (VAS) for pain [ Time Frame: 6 months ]
  2. Oswestry Disability Index to assess Activity of Daily Living [ Time Frame: 6 months ]
  3. Roland Morris Disability Questionnaire to assess Activity of Daily Living [ Time Frame: 6 months ]
  4. Patient Global Impression of Change pain self-assessment scale to assess Quality of Life [ Time Frame: 6 months ]
  5. SF-36 to assess Quality of Life [ Time Frame: 6 months ]
  6. Disc space height by X-ray [ Time Frame: 6 months ]
  7. Pfirrmann Score by MRI [ Time Frame: 6 months ]
  8. PK of AMG0103: Cmax [ Time Frame: 1 month ]
    Maximum plasma concentration estimate for a single injection of AMG0103

  9. PK of AMG0103: Tmax [ Time Frame: 1 month ]
    Time to maximum plasma concentration estimate for a single injection of AMG0103

  10. PK of AMG0103: AUC [ Time Frame: 1 month ]
    Area under the plasma-concentration time curve (AUC) estimate for a single injection of AMG0103

  11. Amount of AMG0103 excreted into urine [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, between 18 and 75 years of age, inclusive, and skeletally mature, in the opinion of the investigator.
  2. Has provided written informed consent before undergoing any study-specific procedures.
  3. Has chronic low back pain for at least 6 months, where back pain is greater than leg pain.
  4. Has separate low back pain and leg pain VAS scores within the following parameters:

    1. Average low back pain VAS score of at least 40 mm and less than 90 mm on a 100 mm visual analog scale.
    2. Average leg pain VAS score that is less than or equal to 50% of the average low back pain VAS score above, where leg pain VAS scores are measured on a 100 mm visual analog scale.
  5. Has had inadequate response to conservative medical care over a period of at least 3 months.
  6. Diagnosis of painful degenerative disc disease at one lumbar level from L1 to S1 confirmed by subject history and radiographic studies (eg, MRI, x-rays). Radiographic studies must demonstrate the following:

    1. A Pfirrmann score of 3 or 4 on MRI in just a single disc between L1 and S1
    2. With or without contained disc herniations of <3 mm protrusion with no radiographic evidence of neurologic compression
    3. Disc height loss of the symptomatic disc is less than 50% of the adjacent discs
    4. All discs other than the index disc must have a Pfirrman score of less than 3
    5. No spondylolisthesis or instability on flexion/extension views of more than 1-2 mm
    6. No evidence of sacroiliac, or extra-spinal, pathology that could account for lumbar back pain
    7. No more fluid in, or widening of, the facet joints around the symptomatic disc than is seen on the other facet joints of "normal" levels
  7. Has a Body Mass Index (BMI) between 15.0 and 35.0 kg/m2 at the screening visit.
  8. Oswestry Disability Index score of at least 30 and not more than 90 on the 100 point questionnaire.
  9. Willing and able to comply with all protocol requirements.
  10. Females of childbearing potential must agree to use highly effective methods of contraception during heterosexual intercourse from the date they sign the ICF until 1 year after the single dose of study drug is administered.
  11. Male subjects must agree that, if their partner is of childbearing potential, they and the partner will use an appropriate method of contraception as defined above.

Exclusion Criteria:

  1. Has any prior or current medical condition (eg, an active systemic infection), including known bleeding disorders that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements.
  2. Has any clinically significant finding on a screening evaluation that in the judgment of the Investigator would preclude safe study completion.
  3. Liver function tests >1.5 the upper limit of normal (ULN) for alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST)
  4. Serum creatinine >1.5 ULN at screening
  5. Blood pressure >160/110 mm Hg recorded on 3 readings at screening and/or resting pulse >120 beats/min at screening
  6. Body temperature ≥101°F on day of planned injection
  7. Has a co-morbid medical condition of the spine or the upper extremities that may affect neurological and/or pain assessments as specified in the protocol, including spinal fusion, spondylolysis and spondylolisthesis.
  8. Has evidence of hip pathology based on clinical history, physical exam and/or radiographic imaging that could be the source of lumbar back pain.
  9. Has a history of an endocrine or metabolic disorder that affects the spine (eg, Paget's disease).
  10. Has a compressive pathology due to stenosis or frankly herniated disc or sequestered discs.
  11. Has symptomatic involvement of more than one lumbar disc, in the opinion of the investigator.
  12. Has an intact disc bulge/protrusion or focal herniation at the symptomatic level >3 mm, the presence of disc extrusion or sequestration, or a complete annular tear.
  13. Has lumbar intervertebral foraminal stenosis at the symptomatic level resulting in clinically significant spinal nerve root compression, in the opinion of the investigator.
  14. Has undergone a previous surgery at the symptomatic disc, or has plans to do so within 6 months of receiving the dose of AMG0103, that has altered the structure of the target disc level, or is likely to do so (eg, laminectomy, foraminotomy, fusion, intradiscal electrothermal therapy, intradiscal radiofrequency, thermocoagulation).
  15. Has had any lumbar intradiscal injection procedure (eg, injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate). Discography may be performed, but must be done at least 3 weeks (or more) prior to the injection procedure in this study.
  16. Has had any epidural steroid injection(s) within 3 months prior to study treatment.
  17. Is a female who is pregnant, planning to become pregnant, or lactating.
  18. Has a PT(INR) and/or aPTT lab result outside of the reference range, or within the last 30 days taken, or is currently on, an anticoagulant therapy (e.g., Warfarin) for the purpose of treating or preventing blood clots.
  19. Has ferromagnetic implants that would disallow MRI of the symptomatic disc.
  20. Is involved in current or pending spinal litigation where permanent disability benefits are being sought.
  21. Has a physical or mental condition (eg, senile dementia, Alzheimer's disease) that would interfere with Subject self-assessment of function, pain or quality of life.
  22. Has a positive screen for Hepatitis B Surface Antigen, Hepatitis C antibodies, or human immunodeficiency virus (HIV) by antibodies or nucleic acid test.
  23. Is an immediate family member (by birth) of any other subject participating in this study.
  24. Has a history of cancer that does NOT have documentation to support a complete and curative treatment.
  25. Has participated within the previous 3 months in an interventional clinical study or is concurrently enrolled in any non-interventional research of any type judged to be scientifically or medically incompatible with this study.
  26. Is transient or has been treated in the 6 months prior to providing informed consent for alcohol and/or drug abuse in an inpatient substance abuse program.
  27. Is currently incarcerated (a prisoner).
  28. Is an Investigator-site employee or immediate family (defined as a spouse, parent, child, or sibling, whether biological or legally adopted) of an Investigator-site employee.
  29. Is a Sponsor employee (permanent, temporary contract worker, or designee responsible for the conduct of the study) or immediate family (defined as a spouse, parent, child, or sibling, whether biological or legally adopted) of a Sponsor employee.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03263611


Contacts
Layout table for location contacts
Contact: AnGes, Inc. International Clinical Development 81-3-5730-2488 gcrinfo@anges.co.jp

Locations
Layout table for location information
United States, California
Keck Medicine of USC Recruiting
Los Angeles, California, United States, 90033
Contact: Lena Galian    323-442-5303    lena.galian@med.usc.edu   
University of California San Diego Recruiting
San Diego, California, United States, 92037
Contact: Jesal Parekh    858-822-1288    jeparekh@ucsd.edu   
Spine Institute of San Diego Recruiting
San Diego, California, United States, 92120
Contact: Erin Mears    770-365-2555    emears@milestonecro.com   
United States, Florida
Florida Medical Pain Management Recruiting
Saint Petersburg, Florida, United States, 33709
Contact: Yulissa Peguero    727-548-6100 ext 280    YPeguero@FMPM.com   
United States, Illinois
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Susan Dvojack    312-942-6689    Susan_Dvojack@rush.edu   
Sponsors and Collaborators
AnGes, Inc.
Investigators
Layout table for investigator information
Study Director: AnGes, Inc. Clinical Development AnGes, Inc.

Layout table for additonal information
Responsible Party: AnGes, Inc.
ClinicalTrials.gov Identifier: NCT03263611     History of Changes
Other Study ID Numbers: AMG0103-US-01
First Posted: August 28, 2017    Key Record Dates
Last Update Posted: August 17, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by AnGes, Inc.:
disc degeneration
Intervertebral disc
discogenic pain
chronic discogenic lumbar back pain

Additional relevant MeSH terms:
Layout table for MeSH terms
Back Pain
Intervertebral Disc Degeneration
Low Back Pain
Pain
Neurologic Manifestations
Signs and Symptoms
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases